Fluticasone furoate/Umeclidinium/Vilanterol
Indication
Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.
Green (Restricted)
Brand:
Trelegy Ellipta®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Respiratory system
Background
Trelegy Ellipta® inhalation powder is recommended as an option for the treatment of COPD with the following restriction:
Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy.
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: